Revium Rx Statistics
Total Valuation
Revium Rx has a market cap or net worth of 30.36 million. The enterprise value is 30.71 million.
| Market Cap | 30.36M |
| Enterprise Value | 30.71M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Revium Rx has 60.73 million shares outstanding.
| Current Share Class | 60.73M |
| Shares Outstanding | 60.73M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +2.50% |
| Owned by Insiders (%) | 47.09% |
| Owned by Institutions (%) | n/a |
| Float | 32.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 5.53 |
| P/TBV Ratio | 5.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -44.96 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -48.75 |
Financial Position
The company has a current ratio of 39.08, with a Debt / Equity ratio of 0.00.
| Current Ratio | 39.08 |
| Quick Ratio | 38.13 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -226.67 |
Financial Efficiency
Return on equity (ROE) is -23.25% and return on invested capital (ROIC) is -14.46%.
| Return on Equity (ROE) | -23.25% |
| Return on Assets (ROA) | -13.96% |
| Return on Invested Capital (ROIC) | -14.46% |
| Return on Capital Employed (ROCE) | -12.40% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -136,600 |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.26% in the last 52 weeks. The beta is -1.26, so Revium Rx's price volatility has been lower than the market average.
| Beta (5Y) | -1.26 |
| 52-Week Price Change | -73.26% |
| 50-Day Moving Average | 0.50 |
| 200-Day Moving Average | 0.61 |
| Relative Strength Index (RSI) | 99.07 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -680,000 |
| Pretax Income | -683,000 |
| Net Income | -683,000 |
| EBITDA | -678,000 |
| EBIT | -680,000 |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
The company has 5.48 million in cash and 1,000 in debt, giving a net cash position of 5.48 million or 0.09 per share.
| Cash & Cash Equivalents | 5.48M |
| Total Debt | 1,000 |
| Net Cash | 5.48M |
| Net Cash Per Share | 0.09 |
| Equity (Book Value) | 5.49M |
| Book Value Per Share | 0.16 |
| Working Capital | 5.48M |
Cash Flow
In the last 12 months, operating cash flow was -629,000 and capital expenditures -1,000, giving a free cash flow of -630,000.
| Operating Cash Flow | -629,000 |
| Capital Expenditures | -1,000 |
| Free Cash Flow | -630,000 |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Revium Rx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -50,140.35% |
| Shareholder Yield | -50,140.35% |
| Earnings Yield | -2.25% |
| FCF Yield | -2.07% |
Stock Splits
The last stock split was on December 9, 2020. It was a reverse split with a ratio of 0.002.
| Last Split Date | Dec 9, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.002 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |